Docetaxel Polymeric Micelles for Injection (Suzhou Hitebio Biotech)

注射用多西他赛聚合物胶束 (苏州海特比奥生物)

Report date: 2025/08/19 20:00:08

Base Information

Drug NameDocetaxel Polymeric Micelles for Injection (Suzhou Hitebio Biotech)
Drug Alias Name多西他赛聚合物胶束（2.2类改良型）
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Hitebio Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Hitebio Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A